I'm LongbridgeAI, I can summarize articles.EPS: As of FY2025 Q2, the actual value is USD -0.56, missing the estimate of USD -0.4243.
EBIT: As of FY2025 Q2, the actual value is USD -26.66 M, missing the estimate of USD -24.23 M.
Segment Revenue
- Research and Development: $17.4 million for the three months ended June 30, 2025, compared to $15.5 million for the same period in 2024, and $33.9 million for the six months ended June 30, 2025, compared to $29.9 million for the same period in 2024.
- General and Administrative: $10.1 million for the three months ended June 30, 2025, compared to $6.9 million for the same period in 2024, and $17.0 million for the six months ended June 30, 2025, compared to $14.0 million for the same period in 2024.
Operational Metrics
- Net Loss: $26.7 million for the three months ended June 30, 2025, compared to $21.2 million for the same period in 2024, and $49.1 million for the six months ended June 30, 2025, compared to $41.2 million for the same period in 2024.
Cash Flow
- Net Cash Used in Operating Activities: - $44.4 million for the six months ended June 30, 2025, compared to - $37.4 million for the same period in 2024.
- Net Cash Provided by Investing Activities: $33.0 million for the six months ended June 30, 2025, compared to $17.5 million for the same period in 2024.
- Net Cash Provided by Financing Activities: $13.5 million for the six months ended June 30, 2025, compared to $5.2 million for the same period in 2024.
Unique Metrics
- Cash, Cash Equivalents, and Marketable Securities: $67.0 million as of June 30, 2025.
Future Outlook and Strategy
- Core Business Focus: Vigil Neuroscience, Inc. is focused on developing VG-3927, a small molecule TREM2 agonist for Alzheimer’s disease, and has entered into a merger agreement with Sanofi, which is expected to close in the third quarter of 2025.
- Non-Core Business: The rights to iluzanebart will be returned to Amgen Inc. as part of the merger agreement with Sanofi.